Resmiterom Efficacy & Safety in Patients With MASH

Inclusion Criteria: * • At least one metabolic comorbidity (e.g., T2DM, obesity, dyslipidemia and hypertension) * Clinical diagnosis of MASH using: * LSM ≥ 8.5kpa And/or * FAST score ≥0.67 And/or * FibroScan CAP ≥ 275 dB/m And/or * FIB-4 \> 1.3 Exclusion Criteria: * • History of drug addiction and alcoholism * Cirrhosis or decompensated liver disease * Chronic viral hepatitis HBV, HCV) * MACE including MI, Stroke, PE etc. * Pregnant/lactating women * Concurrent use of other investigational drugs * History of other liver diseases (viral, autoimmune, drug-induced, alcohol) * Previous use of resmetirom in last 6 months * Significant renal impairment (eGFR \<30)